View Cart  

EU Issues Draft Guidance on Marketing Authorization of Transdermal Patches

A A
Manufacturers of transdermal patches should minimize the amount of residual drug substance in the patch as much as possible to avoid patient and environmental safety risks, according to a new European Medicines Agency (EMA) draft guideline.

To View This Article:

Login

Subscribe To International Medical Device Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00